Antrostomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Antrostomy is a surgical procedure that creates or enlarges an opening (ostium) into the maxillary antrum — the largest of the paranasal sinuses, located in the cheekbone on either side of the nose. The purpose is to establish ventilation and drainage of a sinus that has become blocked, allowing chronic infection, polyps, or accumulated mucus to be cleared and normal mucociliary clearance to be restored. The term derives from the Latin antrum (cave) and the Greek stoma (opening/mouth).

The maxillary antrum is the most frequently affected sinus in sinusitis, partly because its natural drainage ostium opens near the roof of the sinus rather than at its floor — a gravitationally disadvantaged anatomy that predisposes to mucus accumulation when mucosal swelling obstructs the ostium. Antrostomy enlarges this natural opening (middle meatal antrostomy) or creates a new, larger drainage window in the inferior meatus (inferior meatal antrostomy), allowing gravity-dependent drainage and instrument access for sinus clearance.

In modern ENT practice, antrostomy is most commonly performed as part of Functional Endoscopic Sinus Surgery (FESS), using rigid nasal endoscopes to visualise the sinus interior under direct magnified vision and powered microdebriders or cutting instruments to enlarge the natural ostium under endoscopic guidance. This approach has largely replaced the older Caldwell-Luc operation (which used a sublabial incision to directly enter the maxillary antrum from below the upper lip) due to its superior visualisation, reduced morbidity, and better outcomes.

Chronic maxillary sinusitis — persistent sinus inflammation lasting more than 12 weeks despite adequate medical therapy (nasal steroid sprays, saline irrigation, and antibiotic courses for acute exacerbations) — is the primary indication for antrostomy. CT scanning of the paranasal sinuses is used to confirm the diagnosis and extent of disease before surgical planning. Recurrent acute sinusitis (4 or more acute episodes per year with complete resolution between episodes) is another indication when underlying anatomical obstruction is identified.

Maxillary sinus polyps or mucoceles — fluid-filled cysts that can expand to erode adjacent structures — require surgical drainage and removal through the antrostomy. Fungal sinusitis (allergic fungal sinusitis or invasive fungal infection in immunocompromised patients) requires thorough surgical clearance of the sinus, which depends on adequate antrostomy access. Antrostomy provides access for biopsy of sinus tumours and for irrigation and lavage procedures in specific clinical circumstances.

Patients with symptomatic chronic maxillary sinusitis — characterised by nasal obstruction, anterior or posterior nasal discharge, facial pain/pressure, and reduced or absent sense of smell — who have undergone at least 8–12 weeks of intensive medical therapy (nasal steroid spray, twice-daily saline irrigation, and appropriate antibiotic therapy for acute exacerbations) without resolution are candidates for surgical evaluation. CT scan findings of mucosal thickening, opacification, or polyps in the maxillary sinus that correlate with symptoms confirm the indication.

Contraindications include active acute bacterial sinusitis with fever (surgery should be deferred until after the acute episode is resolved), bleeding disorders or anticoagulation that cannot be safely managed perioperatively, and severe nasal polyposis requiring more extensive surgical clearance beyond isolated antrostomy. Patients with uncontrolled systemic disease should be medically optimised before elective sinus surgery. Aspirin-exacerbated respiratory disease (Samter's triad — nasal polyps, asthma, aspirin sensitivity) represents a complex clinical scenario requiring careful pre-operative medical management.

Middle meatal antrostomy — enlargement of the natural maxillary sinus ostium, which opens into the middle meatus of the nasal cavity — is the standard modern technique, performed as part of FESS under general or local anaesthesia with topical vasoconstrictors (cocaine or oxymetazoline). The natural ostium is identified endoscopically and enlarged anteriorly and inferiorly using punch forceps or a powered microdebrider, creating an opening typically 1–2 cm in diameter. This restores the natural drainage pathway and maintains mucociliary transport function.

Inferior meatal antrostomy — creating a new window in the inferior wall of the maxillary sinus below the inferior turbinate — was the traditional approach but is now largely obsolete as it bypasses mucociliary transport and does not restore physiological drainage. It is occasionally used in modified form for irrigation and lavage access. The Caldwell-Luc operation (open maxillary sinus surgery via a sublabial incision) is now reserved for very specific indications: extensive bony disease, tumour removal, or cases where endoscopic access is not feasible. Balloon sinuplasty — dilatation of the maxillary ostium using a small balloon catheter — is a less invasive office-based or operating theatre option for selected patients with isolated ostial obstruction and minimal mucosal disease.

Selecting the most appropriate Antrostomy — Surgical Treatment Guide approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Endoscopic middle meatal antrostomy achieves clinically significant symptom improvement in 80–90% of appropriately selected patients with chronic maxillary sinusitis. Improvement in nasal symptoms (discharge, blockage, facial pressure) is typically apparent within 4–8 weeks of surgery as post-operative swelling resolves. Quality of life measures (SNOT-22 — Sino-Nasal Outcome Test) demonstrate significant improvement at 3 months and are maintained at 1 and 5 years in the majority of patients.

For patients with maxillary sinus polyps, antrostomy combined with polypectomy achieves clearance and symptom resolution, though polyps frequently recur (in up to 40–50% of cases with eosinophilic polyposis) and long-term management with nasal steroid sprays and saline irrigation is essential. Biologic therapy (dupilumab, mepolizumab) for chronic rhinosinusitis with nasal polyps (CRSwNP) is transforming outcomes for recurrent polyposis, reducing the need for repeated surgery in responders.

FESS-related antrostomy complications include bleeding (the most common complication, typically minor and managed with post-operative nasal packing or vasoconstrictors), orbital complications (periorbital bruising, orbital haematoma, and in very rare cases, orbital injury causing diplopia or vision loss from injury to the lamina papyracea — the thin bony orbital wall adjacent to the ethmoid sinuses), and very rarely, intracranial complications from injury to the skull base or dura.

Infraorbital nerve injury causing facial numbness is rare with modern technique. Nasolacrimal duct injury causing epiphora (watering eye) occurs in less than 1% of cases. Post-operative adhesion formation (synechiae) between the antrostomy margins and adjacent structures can lead to closure of the surgically created opening, requiring revision surgery in 5–10% of cases. Septal perforation is a rare complication if the nasal septum is traumatised. General anaesthesia risks apply as with any procedure requiring general anaesthesia.

Most antrostomy procedures are performed as day-case procedures under general anaesthesia. Patients are discharged with nasal saline irrigation instructions (twice daily high-volume nasal saline rinse using a neti pot or sinus rinse bottle), topical nasal steroid spray, and oral antibiotics for 5–7 days. Nasal packing, if used, is typically removed within 24–48 hours. Crusting and blood-stained discharge are expected for 1–2 weeks post-operatively.

Post-operative endoscopic debridement (removal of crusts and clots under nasal endoscopy) is performed at 1–2 weeks and 4–6 weeks in the clinic to maintain patency and prevent adhesion formation — this is a critical component of post-operative care in FESS. Physical activity can resume gradually at 1–2 weeks; blowing the nose forcefully is restricted for the first 2 weeks. Full benefit is typically apparent at 3 months. Long-term nasal steroid spray is continued indefinitely in patients with polyps and in those with underlying allergic rhinitis.

FESS with antrostomy in the United States costs approximately $5,000–15,000 as a day-case procedure, depending on the extent of surgery (unilateral vs bilateral, additional sinus procedures performed). The increasing adoption of balloon sinuplasty, which can be performed in an office setting under local anaesthesia, offers a less costly alternative for selected patients (approximately $2,000–5,000 in the US). Insurance coverage is generally available for chronic sinusitis when medical criteria are met.

For patients seeking ENT surgery abroad, FESS with antrostomy at accredited hospitals in India costs $600–2,000 — a saving of 75–90% versus US prices. Thailand and Turkey offer comparable ENT procedures at $800–3,000. Indian ENT surgeons at major hospitals use modern Karl Storz or Olympus endoscopic equipment and perform high volumes of FESS surgery. The post-operative saline irrigation protocol is easily maintained at home after returning from abroad.

Conservative medical management remains the first-line approach for most cases of chronic maxillary sinusitis. High-volume nasal saline irrigation (500 mL per side, twice daily) is the most evidence-based intervention for reducing symptoms and mucosal inflammation. Intranasal corticosteroid sprays (mometasone, fluticasone, budesonide) reduce mucosal oedema and polyp size. A defined course of systemic oral corticosteroids (prednisolone) for 1–3 weeks can shrink polyps and provide temporary symptomatic relief.

Biologic therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP) has transformed management: dupilumab (anti-IL-4/IL-13), omalizumab (anti-IgE), and mepolizumab (anti-IL-5) significantly reduce polyp burden and sinus symptoms in patients with type 2 inflammatory disease, potentially reducing or deferring the need for surgical intervention. For patients with allergic rhinitis driving maxillary sinusitis, allergen immunotherapy addresses the underlying sensitisation. Antral washout — irrigation of the maxillary sinus through a needle puncture under local anaesthesia — is a minor procedure providing temporary drainage and bacterial culture but has been largely replaced by FESS in contemporary practice.